Testing a new sensor for EGFR mutations in lung cancer
Part of Cancer clinical trials.
This trial is testing a new type of sensor that uses a chemical reaction to detect specific EGFR mutations in advanced lung cancer patients. The goal is to help doctors choose the most effective treatment based on the patient's genetic profile.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lung cancer that has been staged using the TNM system (9th edition).
- You are willing to take part in the study and follow its plan.
- You or your legal representative can sign a consent form approved by the ethics committee.
- You do not currently have any other active cancer.
- You do not have a serious lung condition like bronchiectasis, asthma, or COPD, and you have not been exposed to dust, mines, or asbestos at work.
- You have your baseline health information available.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if regular blood tests can help guide chemotherapy treatment before surgery for people with a specific type of lung cancer called EGFR-mutant non-small cell lung cancer. It aims to see if these blood tests can show how well the cancer is responding, potentially allowing doctors to adjust treatment for better outcomes.
This study looks at why certain EGFR-positive advanced lung cancers resist third-generation EGFR tablet treatment given as the first treatment. Your body samples and scan results help researchers understand the resistance, which may guide better future care.
This study looks at how EGFR-mutated lung cancer changes over time and tries to find markers that can predict how well you might respond to treatment. You will provide a tumor sample for genetic analysis.
This trial tests a new drug called ANS02 in people with non-small cell lung cancer (a common type of lung cancer) that has a specific genetic change called an EGFR mutation. The drug is designed to target and slow cancer growth in people with this mutation.
This trial is testing a new imaging probe that binds to EGFR mutations, which are common in some lung cancers. If you have lung cancer with a confirmed EGFR mutation, this scan may help doctors see your cancer more clearly.
This study looks at real-world treatment for non-small cell lung cancer with a specific genetic change (EGFR mutation). It might help researchers understand how different treatments work in daily practice.
Hear when a new Lung Cancer in Normal and Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.